Last reviewed · How we verify
Lorazepam Mylan
Lorazepam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability.
Lorazepam enhances the inhibitory effects of GABA at GABA-A receptors in the central nervous system, reducing neuronal excitability. Used for Anxiety disorders, Acute seizures and seizure prophylaxis, Insomnia.
At a glance
| Generic name | Lorazepam Mylan |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Drug class | Benzodiazepine |
| Target | GABA-A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Lorazepam is a benzodiazepine that binds to GABA-A receptors and potentiates the effect of the inhibitory neurotransmitter GABA, leading to increased chloride ion influx and neuronal hyperpolarization. This results in sedative, anxiolytic, anticonvulsant, and muscle relaxant effects. The drug is commonly used for acute anxiety, seizure management, and sedation in clinical settings.
Approved indications
- Anxiety disorders
- Acute seizures and seizure prophylaxis
- Insomnia
- Alcohol withdrawal
- Preoperative sedation
Common side effects
- Sedation/drowsiness
- Dizziness
- Ataxia/coordination impairment
- Dependence/withdrawal risk
- Respiratory depression
- Cognitive impairment
Key clinical trials
- Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability (PHASE4)
- Fasting Study of Lorazepam Tablets 2 mg and Ativan Tablets 2 mg (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |